China Universal CSI Health Care ETF(159929) Rises 1.19% Intraday,Institutions Note Core Product Volume Growth Driven by Medical Insurance Supports Performance

NewTimeSpace News: As of 14:16 on February 4, 2026, the CSI Medical & Health Index (000933) surged 1.22%. Among its constituent stocks, Yifeng Pharmacy rose 4.79%, Zaijing Pharmaceutical climbed 4.40%, Salubris Pharmaceuticals advanced 4.07%, while other stocks such as Dong'e Ejiao and Jichuan Pharmaceutical followed suit. TheChina Universal CSI Health Care ETF (159929) rose 1.19% to close at RMB 1.36. Over a longer time frame, as of February 3, 2026, the ETF had achieved a cumulative increase of 10.55% in the past year. (The stocks listed above are merely constituent stocks of the index and do not constitute specific investment recommendations.)

In terms of liquidity, theChina Universal CSI Health Care ETF recorded an intraday turnover rate of 2.82% and a trading volume of RMB 69.1464 million. Looking back, as of February 3, the ETF's average daily trading volume in the past week reached RMB 128 million.

Regarding scale, the latest size of theChina Universal CSI Health Care ETF stood at RMB 2.447 billion, a new high in nearly three months. (Data source: Wind)

In terms of share count, the latest share of theChina Universal CSI Health Care ETF reached 1.824 billion units, a new high in nearly six months. (Data source: Wind)

For capital inflows, theChina Universal CSI Health Care ETF achieved consecutive net capital inflows over the recent 13 days, with the highest single-day net inflow of RMB 68.0306 million, accumulating a total of RMB 426 million in "capital absorption" and an average daily net inflow of RMB 32.7969 million. (Data source: Wind)

Data shows that leveraged capital has been continuously deploying in the ETF. TheChina Universal CSI Health Care ETF recorded net purchases by leveraged capital for three consecutive days, with the highest single-day net purchase of RMB 7.4080 million, and the latest margin trading balance stood at RMB 103 million. (Data source: Wind)

As of February 3, theChina Universal CSI Health Care ETF had a net asset value (NAV) increase of 14.29% in the past two years. In terms of profitability, as of February 3, 2026, since its establishment, the ETF has achieved a maximum monthly return of 23.11%, the longest consecutive monthly growth period of 8 months with a cumulative increase of 63.16%, a ratio of rising to falling months of 79:70, an average monthly return of 5.34% in upward months, and a 62.19% profit probability for a 3-year historical holding period. As of February 3, 2026, the ETF's annualized excess return over the benchmark in the past two years was 1.24%.

Regarding drawdown, as of February 3, 2026, the ETF's maximum drawdown since the beginning of the year was 8.57%, with a relative benchmark drawdown of 0.02%.

In terms of fees, theChina Universal CSI Health Care ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%.

For tracking accuracy, as of February 3, 2026, the ETF's tracking error in the past month was 0.011%.

Notably, the valuation of the CSI Medical & Health Index tracked by the fund is at a historical low. The latest price-to-book ratio (PB) is 3.18 times, lower than 86.33% of the time since the index was established, highlighting prominent valuation cost-effectiveness.

TheChina Universal CSI Health Care ETF closely tracks the CSI Medical & Health Index. To reflect the overall performance of listed company securities in different industries within the CSI 800 Index sample and provide analytical tools for investors, the CSI 800 Index sample is classified into 11 primary industries and 35 secondary industries according to the CSI Industry Classification. Indices are then compiled using all securities in each primary and secondary industry as samples, forming the CSI 800 Industry Indices.

Data shows that as of January 30, 2026, the top 10 weight stocks of the CSI Medical & Health Index (000933) were WuXi AppTec Co., Ltd., Hengrui Medicine Co., Ltd., Mindray Medical International Limited, United Imaging Healthcare Co., Ltd., Aier Eye Hospital Group Co., Ltd., Yunnan Baiyao Group Co., Ltd., Pien Tze Huang Pharmaceutical Co., Ltd., NHU Co., Ltd., Kelun Pharmaceutical Co., Ltd., and Fosun Pharmaceutical (Group) Co., Ltd., with a combined weight of 43.2%. (The stocks listed above are merely constituent stocks of the index and do not constitute specific investment recommendations.)

Donghai Securities stated that the innovative drug sector entered an accelerated period of profit realization in 2025. The volume growth of core products supported by medical insurance has become the foundation for performance growth, while external cooperation such as BD (Business Development) has emerged as an important driver for performance improvement. This has further focused the sector's investment logic on "genuine profitability and solid innovation".

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.